Viscosupplementation Global Market Report 2024

The viscosupplementation market size has grown rapidly in recent years. It will grow from $3.74 billion in 2023 to $4.15 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth observed in the historic period can be attributed to several factors, including an aging population, increasing rates of obesity, improved insurance coverage, heightened awareness among individuals, patient preferences, and a notable rise in cases related to osteoarthritis. These elements collectively contributed to the expansion and adoption of viscosupplementation treatments during this period.

The viscosupplementation market size is expected to see rapid growth in the next few years. It will grow to $6.19 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The projected growth in the upcoming period can be linked to several factors such as continued regulatory backing, the emergence of alternative payment structures, amplified healthcare expenditure, ongoing research and development efforts, and the widening of treatment applications. Key trends anticipated during this period encompass outcome-centric payment frameworks, initiatives focused on educating patients, advancements in biomarker development, ongoing exploration of gene therapy, and the implementation of value-based care models. These trends are expected to shape and drive the expansion of viscosupplementation practices in healthcare.

The increasing prevalence of osteoarthritis is poised to be a significant driver for the viscosupplementation market in the foreseeable future. Osteoarthritis, a degenerative joint disease and a common form of arthritis, manifests in the breakdown of joints, particularly in areas such as the hips, knees, and hands. Viscosupplementation treatment, involving the direct injection of hyaluronic acid into bone joints, serves to alleviate pain and enhance smooth bone movement. According to the Centers for Disease Control and Prevention (CDC), an American public health service organization, a projected 78.4 million adults aged 18 years and older in the USA are expected to be afflicted by arthritis by the year 2040. This underscores the pivotal role of the rising prevalence of osteoarthritis in propelling the growth trajectory of the viscosupplementation market.

Anticipated growth in healthcare expenditure is set to foster the expansion of the viscosupplementation market in the coming years. Healthcare expenditure, denoting the total spending on healthcare costs, encompasses the financial outlay on healthcare-related goods and services within a specific healthcare system or economy. The surge in healthcare expenditure plays a pivotal role in advancing the broader adoption and increased accessibility of viscosupplementation. This support extends to various aspects, including research, training, infrastructure development, and coverage by healthcare plans, ultimately benefiting individuals grappling with joint-related issues. As of November 2022, the Canadian Institute for Health Information, a U.S.-based not-for-profit organization, reported a notable increase in healthcare expenditure to 0.8%, reaching $331 billion in 2022, compared to 7.6% in 2021. Consequently, the upward trajectory of healthcare expenditure emerges as a driving force behind the growth of the viscosupplementation market.

The viscosupplementation market is witnessing a surge in popularity driven by advancements in technology. Companies within this market are strategically embracing new technologies to maintain their competitive edge. In August 2021, Seikagaku Corporation, a prominent Japanese pharmaceutical firm, unveiled HyLink, an innovative viscosupplement designed for intra-articular single injection to address knee osteoarthritis. HyLink incorporates cross-linking technology, a method used to create a long-lasting cross-linked hyaluronate hydrogel that effectively persists in the joint cavity, establishing it as a durable treatment solution. This move reflects Seikagaku Corporation's commitment to staying at the forefront of technological developments within the viscosupplementation sector.

Leading companies in the viscosupplementation market are actively pursuing innovation to secure a competitive advantage. A notable example is Nuvo Pharmaceuticals Inc., a Canada-based pharmaceutical company, which, in January 2021, introduced NeoVisc+ 2 mL and NeoVisc ONE 4 mL in the Canadian market. These products are hyaluronic acid (HA) viscosupplements specifically designed to address pain relief and enhance joint functionality in patients with degenerative or mechanical arthropathy of the knee, commonly associated with osteoarthritis. The launch of NeoVisc+ 2 mL and NeoVisc ONE 4 mL underscores Nuvo Pharmaceuticals Inc.'s dedication to delivering cutting-edge treatment options for knee pain and osteoarthritis, contributing to the overall growth of the viscosupplementation market in Canada.

In December 2021, Avanos Medical Inc., a medical technology company based in the United States, successfully completed the acquisition of OrthogenRx Inc. for a total transaction value of $160 million. This strategic move significantly expanded, diversified, and enhanced Avanos Medical Inc.'s chronic pain product portfolio, specifically by incorporating treatment options for individuals with knee osteoarthritis. The acquisition was strategically aligned with the company's objective to fortify its partnerships with healthcare providers on a global scale, particularly in the realm of musculoskeletal pain treatment. OrthogenRx Inc., a U.S.-based medical device company with expertise in viscosupplementation therapies for knee osteoarthritis, played a pivotal role in reinforcing Avanos Medical Inc.'s position in this therapeutic space.

Major companies operating in the viscosupplementation market report are Seikagaku Corporation, Anika Therapeutics Inc., Bioventus LLC, Sanofi S.A., Zimmer Biomet, Avanos Medical Inc., Johnson & Johnson Services Inc., Aptissen S.A., Smith & Nephew Plc., Teva Pharmaceutical Industries Ltd., Merck KGaA, Flexion Therapeutics Inc., Regen Lab SA, OrthogenRx Inc., Fidia Farmaceutici S.P.A, Ferring Pharmaceuticals, Wellchem Pharmaceuticals Pte Ltd., Chugai Pharmaceutical Corp., Laboratoires VIVACY, LG Life Sciences Ltd., Miravo Healthcare, Neopharmed Gentili S.p.A., SingHealth Group., Viatris, Allergan, Hoffmann-La Roche, Meda Pharmaceuticals, Merz Pharma, Mylan N.V., Novartis International AG.

North America was the largest region in the viscosupplementation market in 2023. The regions covered in the viscosupplementation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viscosupplementation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of viscosupplementation include single-injection, three-injection, and five-injection methods. Single-injection viscosupplementation entails a direct injection of hyaluronic acid into the knee's diarthrodial joints, restoring the synovial fluid's rheological properties to generate anti-inflammatory and analgesic effects. Hyaluronic acid variations such as standard and stabilized forms, sourced from avian and non-avian origins, are used to address various osteoarthritic conditions such as knee, hip, and hand osteoarthritis. These treatments are administered across diverse healthcare settings, including hospitals, ambulatory surgical centers, among others.

The viscosupplementation market research report is one of a series of new reports that provides viscosupplementation market statistics, including viscosupplementation industry global market size, regional shares, competitors with a viscosupplementation market share, detailed viscosupplementation market segments, market trends, and opportunities, and any further data you may need to thrive in the viscosupplementation industry. This viscosupplementation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.